Everest Medicines Sees Differentiated Strategy Leading To Trodelvy Success

China Situation Key

Focused on the Chinese Market, the Shanghai-based bioventure is pushing ahead with a differentiated clinical development strategy for its top in-licensed asset Trodelvy, as an uphill fight looms over the antibody-drug conjugate therapy outside of China, the company’s president says in an interview.

China pharma market — Everest Medicines bets on familiarity with local market amid strong headwinds for business model it is built o. • Source: Alamy

Hong Kong-listed Everest Medicines Limited, which is relying on in-licensing western drugs to China and other markets in Asia, is betting on the benefits of familiarity with local markets, amid strong headwinds against the very business model it is built on.

The Shanghai-based biotech, established in 2017, is developing a portfolio of 11 in-licensed, clinical-stage assets against a backdrop of fast-changing...